Building a new ecosystem for precision medicine — connecting global biomedical innovation with clinical practice.
NovoBay Biotechnology Company Limited is a Hong Kong-based biotechnology company dedicated to bridging global biomedical innovation with clinical practice.
Leveraging advanced molecular diagnostics as our entry point, we provide cutting-edge companion diagnostics solutions for multinational pharmaceutical companies, clinical research institutions, and drug trial centers — driving the global accessibility of precision medicine.
Headquartered in Hong Kong, with presence in Shenzhen, Hangzhou, and Beijing, Novobay operates at the intersection of global innovation and local clinical need.
Hong Kong HQ, operations across mainland China
PCR POCT + Nanopore sequencing integration
End-to-end companion diagnostics support
Multi-center trial deployment capability
Novobay Biotech was born from a simple but urgent observation: the gap between biomedical innovation and clinical access remains stubbornly wide.
While breakthrough therapies emerge at an accelerating pace, the companion diagnostics infrastructure needed to deliver them to patients lags behind — especially in resource-limited and emerging markets.
Our founders — a veteran of multinational pharmaceutical medical affairs and a cross-border finance and legal expert — came together with a shared conviction: that advanced molecular diagnostics should not be a bottleneck but an enabler for precision medicine worldwide.
Headquartered in Hong Kong, with presence in Shenzhen, Hangzhou, and Beijing, Novobay operates at the intersection of global innovation and local clinical need. Our dual-platform approach — combining PCR POCT and nanopore sequencing — is purpose-built to address the five core challenges of companion diagnostics development, from sample scarcity to global deployment.
Leveraging advanced molecular diagnostics as our entry point, we connect global biomedical innovation resources to provide cutting-edge companion diagnostics solutions for multinational pharmaceutical companies, clinical research institutions, and drug trial centers — driving the global accessibility of precision medicine.
A world where every patient, regardless of geography or healthcare infrastructure, has access to precision diagnostics that match the best available therapies.
Explore our technology platforms or get in touch to discuss collaboration opportunities.